PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMetolazone
Metolazone
Metolazone (metolazone) is a small molecule pharmaceutical. Metolazone was first approved as Diulo on 1982-01-01. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA. The pharmaceutical is active against solute carrier family 12 member 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metolazone
Tradename
Company
Number
Date
Products
MYKROXChartwell PharmaceuticalsN-019532 DISCN1987-10-30
1 products
DIULOG.D. SearleN-018535 DISCN1982-01-01
3 products
ZAROXOLYNi3 PharmaceuticalsN-017386 DISCN1982-01-01
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
metolazoneANDA2024-08-01
mykrox tablets2006-01-12
zaroxolynNew Drug Application2016-08-06
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
heart failureHP_0001635D006333I50
hypertensionEFO_0000537D006973I10
nephrotic syndromeEFO_0004255D009404N04
edemaHP_0000969D004487R60.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03B: Low-ceiling diuretics, excl. thiazides
— C03BA: Sulfonamides, low-ceiling diuretics, plain
— C03BA08: Metolazone
— C03E: Diuretics and potassium-sparing agents in combination
— C03EA: Low-ceiling diuretics and potassium-sparing agents
— C03EA12: Metolazone and potassium-sparing agents
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333HP_0001635I5012413525
HypertensionD006973EFO_0000537I10———123
Acute liver failureD017114HP_0004448————213
Covid-19D000086382—U07.1———112
Iron overloadD019190———1—1—2
Coronavirus infectionsD018352EFO_0007224B34.2———1—1
Renal insufficiencyD051437HP_0000083N19———1—1
Cardiovascular diseasesD002318HP_0001626————1—1
Drug-related side effects and adverse reactionsD064420—T88.7———1—1
EdemaD004487HP_0000969R60.9———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436—N18—1———1
Chronic kidney failureD007676EFO_0003884N18.6—1———1
Kidney diseasesD007674EFO_0003086N08—1———1
Critical illnessD016638———1———1
SepsisD018805HP_0100806A41.9—1———1
Wounds and injuriesD014947—T14.8—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———3————3
CardiomyopathiesD009202EFO_0000318I421————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory insufficiencyD012131HP_0002093J96.9————11
HypernatremiaD006955HP_0003228E87.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMetolazone
INNmetolazone
Description
Metolazone is a quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics. It has a role as a diuretic, an antihypertensive agent and an ion transport inhibitor. It is a member of quinazolines, an organochlorine compound and a sulfonamide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
Identifiers
PDB—
CAS-ID17560-51-9
RxCUI—
ChEMBL IDCHEMBL878
ChEBI ID64354
PubChem CID4170
DrugBankDB00524
UNII IDTZ7V40X7VX (ChemIDplus, GSRS)
Target
Agency Approved
SLC12A3
SLC12A3
Organism
Homo sapiens
Gene name
SLC12A3
Gene synonyms
NCC, TSC
NCBI Gene ID
6559
Protein name
solute carrier family 12 member 3
Protein synonyms
Na-Cl cotransporter, Na-Cl symporter, NaCl electroneutral thiazide-sensitive cotransporter, NCC, sodium-chloride co-transporter, solute carrier family 12 (sodium/chloride transporter), member 3, thiazide-sensitive Na-Cl cotransporter, Thiazide-sensitive sodium-chloride cotransporter
Uniprot ID
P55017
Mouse ortholog
Slc12a3 (20497)
solute carrier family 12 member 3 (P59158)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Metolazone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,206 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,827 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use